請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56378完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳青周(Ching-Chow Chen) | |
| dc.contributor.author | Yi-Hsin Lin | en |
| dc.contributor.author | 林怡忻 | zh_TW |
| dc.date.accessioned | 2021-06-16T05:25:49Z | - |
| dc.date.available | 2019-10-15 | |
| dc.date.copyright | 2014-10-15 | |
| dc.date.issued | 2014 | |
| dc.date.submitted | 2014-08-14 | |
| dc.identifier.citation | Agarwal, Bhendwal, et al. (1999). Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells, 'Clinical cancer research : an official journal of the American Association for Cancer Research' 5 (8):2223-2229.
Al-Lazikani, Banerji, et al. (2012). Combinatorial drug therapy for cancer in the post-genomic era, 'Nature biotechnology' 30 (7):679-692. Aldana-Masangkay Sakamoto (2011). The role of HDAC6 in cancer, 'Journal of biomedicine & biotechnology' 2011 875824. Baker, Preisinger, et al. (1990). p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis, 'Cancer research' 50 (23):7717-7722. Balin-Gauthier, Delord, et al. (2006). In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR, 'Cancer chemotherapy and pharmacology' 57 (6):709-718. Bertout, Patel, et al. (2008). The impact of O2 availability on human cancer, 'Nature reviews. Cancer' 8 (12):967-975. Bipat, Glas, et al. (2004). Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis, 'Radiology' 232 (3):773-783. Bolden, Peart, et al. (2006). Anticancer activities of histone deacetylase inhibitors, 'Nature reviews. Drug discovery' 5 (9):769-784. Bouwman Jonkers (2012). The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance, 'Nature reviews. Cancer' 12 (9):587-598. Brand, Iida, et al. (2011). Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab, 'Cancer Biology & Therapy' 11 (9):777-792. Brenner Hall (2007). Computed tomography--an increasing source of radiation exposure, 'The New England journal of medicine' 357 (22):2277-2284. Brown, Radcliffe, et al. (2003). Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging, 'The British journal of surgery' 90 (3):355-364. Cao, Hou, et al. (2009). Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications, 'BMC cancer' 9 432. Center, Jemal, et al. (2009). International trends in colorectal cancer incidence rates, 'Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology' 18 (6):1688-1694. Chen, Chern, et al. (2013). Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment, 'Journal of medicinal chemistry' 56 (9):3645-3655. Chen, Fischle, et al. (2001). Duration of nuclear NF-kappaB action regulated by reversible acetylation, 'Science (New York, N.Y.)' 293 (5535):1653-1657. Chibaudel, Tournigand, et al. (2012). Therapeutic strategy in unresectable metastatic colorectal cancer, 'Therapeutic advances in medical oncology' 4 (2):75-89. Colakoglu, Nursal, et al. (2010). Effects of different doses of statins on liver regeneration through angiogenesis and possible relation between these effects and acute phase responses, 'Transplantation proceedings' 42 (9):3823-3827. Crea, Nobili, et al. (2011). Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies, 'Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy' 14 (6):280-296. David A. Lieberman (2009). Screening for Colorectal Cancer, 'The New England journal of medicine' 361 1179-1187. Davies, Bignell, et al. (2002). Mutations of the BRAF gene in human cancer, 'Nature' 417 (6892):949-954. de Ruijter AJ (2003). Histone deacetylases (HDACs): characterization of the classical HDAC family. , 'Biochem J ' 370:737-749. Delcuve, Khan, et al. (2013). Targeting class I histone deacetylases in cancer therapy, 'Expert opinion on therapeutic targets' 17 (1):29-41. Demierre, Higgins, et al. (2005). Statins and cancer prevention, 'Nature reviews. Cancer' 5 (12):930-942. Denoyelle, Vasse, et al. (2001). Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study, 'Carcinogenesis' 22 (8):1139-1148. Deroanne, Bonjean, et al. (2002). Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling, 'Oncogene' 21 (3):427-436. Dokmanovic Marks (2005). Prospects: histone deacetylase inhibitors, 'Journal of cellular biochemistry' 96 (2):293-304. Downward (1998). Ras signalling and apoptosis, 'Current opinion in genetics & development' 8 (1):49-54. Duan, Heckman, et al. (2005). Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas, 'Molecular and cellular biology' 25 (5):1608-1619. Duvic, Talpur, et al. (2007). Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL), 'Blood' 109 (1):31-39. Edwards, Chadda, et al. (2012). A systematic review of treatment guidelines for metastatic colorectal cancer, 'Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland' 14 (2):e31-47. Edwards Ericsson (1999). Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway, 'Annual review of biochemistry' 68 157-185. Eot-Houllier, Fulcrand, et al. (2009). Histone deacetylase inhibitors and genomic instability, 'Cancer letters' 274 (2):169-176. Fearon ER ( 2008). Molecular biology of colorectal cancer., 'DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. Vol. 1.' 1218-1231. Finger Giaccia (2010). Hypoxia, inflammation, and the tumor microenvironment in metastatic disease, 'Cancer metastasis reviews' 29 (2):285-293. Gan, Wang, et al. (2008). Synergistic induction of apoptosis by HMG-CoA reductase inhibitor and histone deacetylases inhibitor in HeLa cells, 'Biochemical and biophysical research communications' 365 (2):386-392. Gelmetti, Zhang, et al. (1998). Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO, 'Molecular and cellular biology' 18 (12):7185-7191. Glozak Seto (2007). Histone deacetylases and cancer, 'Oncogene' 26 (37):5420-5432. Gniadecki (2004). Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis, 'Biochemical and biophysical research communications' 320 (1):165-169. Goldstein Brown (1990). Regulation of the mevalonate pathway, 'Nature' 343 (6257):425-430. Gottesman, Fojo, et al. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters, 'Nature reviews. Cancer' 2 (1):48-58. Grady WM ( 2002). Colorectal cancer: genetic alterations, ' Gastrointestinal oncology: principles and practice.' 685-702. Gravalos, Cassinello, et al. (2007). Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer, 'Clinical colorectal cancer' 6 (10):691-699. Greene FL (2002). AJCC cancer staging handbook. 6th ed., 'New York: Springer'. Gronich Rennert (2013). Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates, 'Nature reviews. Clinical oncology' 10 (11):625-642. Group (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), 'Lancet' 344 (8934):1383-1389. GROUP (1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, 'The New England journal of medicine' 339 (19):1349-1357. Gu Roeder (1997). Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain, 'Cell' 90 (4):595-606. Haberland, Montgomery, et al. (2009). The many roles of histone deacetylases in development and physiology: implications for disease and therapy, 'Nature reviews. Genetics' 10 (1):32-42. Hao, Song, et al. (2008). Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells, 'Cancer gene therapy' 15 (7):449-455. Hideshima, Bradner, et al. (2005). Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma, 'Proceedings of the National Academy of Sciences of the United States of America' 102 (24):8567-8572. Hindler, Cleeland, et al. (2006). The role of statins in cancer therapy, 'The oncologist' 11 (3):306-315. Holohan, Van Schaeybroeck, et al. (2013). Cancer drug resistance: an evolving paradigm, 'Nature reviews. Cancer' 13 (10):714-726. Ionov, Peinado, et al. (1993). Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis, 'Nature' 363 (6429):558-561. Issa (2004). CpG island methylator phenotype in cancer, 'Nature reviews. Cancer' 4 (12):988-993. Jackson, Ericsson, et al. (1997). Signaling molecules derived from the cholesterol biosynthetic pathway, 'Sub-cellular biochemistry' 28 1-21. Jenuwein Allis (2001). Translating the histone code, 'Science (New York, N.Y.)' 293 (5532):1074-1080. Jeong, Bae, et al. (2002). Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation, 'Cell' 111 (5):709-720. Johnstone (2002). Histone-deacetylase inhibitors: novel drugs for the treatment of cancer, 'Nature reviews. Drug discovery' 1 (4):287-299. Keyomarsi, Sandoval, et al. (1991). Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin, 'Cancer research' 51 (13):3602-3609. Kim, Blake, et al. (2003). Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA, 'Cancer research' 63 (21):7291-7300. Kinzler KW (2002). The genetic basis of human cancer. 2nd ed, 'New York: McGraw-Hill' 583-612. Kirschner Melton (2010). Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs, 'Anticancer research' 30 (9):3223-3232. Klaus Birchmeier (2008). Wnt signalling and its impact on development and cancer, 'Nature reviews. Cancer' 8 (5):387-398. Kobayashi, Boggon, et al. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, 'The New England journal of medicine' 352 (8):786-792. Konstantinopoulos, Karamouzis, et al. (2007). Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets, 'Nature reviews. Drug discovery' 6 (7):541-555. Kosuri, Wu, et al. (2010). An epigenetic mechanism for capecitabine resistance in mesothelioma, 'Biochemical and biophysical research communications' 391 (3):1465-1470. Kovacs, Murphy, et al. (2005). HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor, 'Molecular cell' 18 (5):601-607. Krusche, Wulfing, et al. (2005). Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis, 'Breast cancer research and treatment' 90 (1):15-23. Kwon, Roh, et al. (2007). Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer, 'Annals of oncology : official journal of the European Society for Medical Oncology / ESMO' 18 (3):504-509. Lee, Ha, et al. (1998). Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells, 'The Journal of biological chemistry' 273 (17):10618-10623. Lengauer, Kinzler, et al. (1997). Genetic instability in colorectal cancers, 'Nature' 386 (6625):623-627. Levin, Lieberman, et al. (2008). Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology, 'Gastroenterology' 134 (5):1570-1595. Li, Jiang, et al. (2011). HDAC6 alpha-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases, 'Journal of the neurological sciences' 304 (1-2):1-8. Lieberman (2009). Clinical practice. Screening for colorectal cancer, 'The New England journal of medicine' 361 (12):1179-1187. Lieberman, Moravec, et al. (2008). Polyp size and advanced histology in patients undergoing colonoscopy screening: implications for CT colonography, 'Gastroenterology' 135 (4):1100-1105. Lieberman, Weiss, et al. (2000). Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380, 'The New England journal of medicine' 343 (3):162-168. Lien Lowman (2008). Therapeutic anti-VEGF antibodies, 'Handbook of experimental pharmacology' (181):131-150. Lin, Lin, et al. (2008). Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2, 'Cancer research' 68 (7):2375-2383. Lord, Brabender, et al. (2002). Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer, 'Clinical cancer research : an official journal of the American Association for Cancer Research' 8 (7):2286-2291. Luger, Mader, et al. (1997). Crystal structure of the nucleosome core particle at 2.8 A resolution, 'Nature' 389 (6648):251-260. Luo, Su, et al. (2000). Deacetylation of p53 modulates its effect on cell growth and apoptosis, 'Nature' 408 (6810):377-381. Lynch de la Chapelle (2003). Hereditary Colorectal Cancer, 'New England Journal of Medicine' 348 (10):919-932. Mandel, Church, et al. (2000). The effect of fecal occult-blood screening on the incidence of colorectal cancer, 'The New England journal of medicine' 343 (22):1603-1607. Markowitz (2007). Aspirin and colon cancer--targeting prevention?, 'The New England journal of medicine' 356 (21):2195-2198. Markowitz Bertagnolli (2009). Molecular Basis of Colorectal Cancer, 'New England Journal of Medicine' 361 (25):2449-2460. Marks (2010). Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions, 'Biochimica et biophysica acta' 1799 (10-12):717-725. Martinez-Balbas, Bauer, et al. (2000). Regulation of E2F1 activity by acetylation, 'The EMBO journal' 19 (4):662-671. Mauchley, Lynge, et al. (2005). Clinical utility and cost-effectiveness of routine preoperative computed tomography scanning in patients with colon cancer, 'American journal of surgery' 189 (5):512-517; discussion 517. Meyerhardt Mayer (2005). Systemic therapy for colorectal cancer, 'The New England journal of medicine' 352 (5):476-487. Minamiya, Ono, et al. (2011). Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung, 'Lung cancer (Amsterdam, Netherlands)' 74 (2):300-304. Minucci Pelicci (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer, 'Nature reviews. Cancer' 6 (1):38-51. Miyashita Reed (1992). bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs, 'Cancer research' 52 (19):5407-5411. Morin, Sparks, et al. (1997). Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC, 'Science (New York, N.Y.)' 275 (5307):1787-1790. Nebbioso, Carafa, et al. (2012). Trials with 'epigenetic' drugs: an update, 'Molecular oncology' 6 (6):657-682. Ness, Zhao, et al. (1996). Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation, 'Archives of biochemistry and biophysics' 325 (2):242-248. New, Olzscha, et al. (2012). HDAC inhibitor-based therapies: can we interpret the code?, 'Molecular oncology' 6 (6):637-656. Palmberg, Koivisto, et al. (1997). Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade, 'European urology' 31 (2):216-219. Parra Verdin (2010). Regulatory signal transduction pathways for class IIa histone deacetylases, 'Current opinion in pharmacology' 10 (4):454-460. Patel, Du, et al. (2004). The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60, 'Molecular and cellular biology' 24 (24):10826-10834. Pouyssegur, Dayan, et al. (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression, 'Nature' 441 (7092):437-443. Qiu, Zhou, et al. (2013). Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials, 'Future oncology (London, England)' 9 (2):255-269. Rockey, Paulson, et al. (2005). Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison, 'Lancet' 365 (9456):305-311. Rohwer Cramer (2011). Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways, 'Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy' 14 (3):191-201. Ruefli, Ausserlechner, et al. (2001). The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species, 'Proceedings of the National Academy of Sciences of the United States of America' 98 (19):10833-10838. Santo, Hideshima, et al. (2012). Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma, 'Blood' 119 (11):2579-2589. Sarkar, Li, et al. (2010). Implication of microRNAs in drug resistance for designing novel cancer therapy, 'Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy' 13 (3):57-66. Semenza (2003). Targeting HIF-1 for cancer therapy, 'Nature reviews. Cancer' 3 (10):721-732. Semenza (2010). Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics, 'Oncogene' 29 (5):625-634. Sentman, Shutter, et al. (1991). bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes, 'Cell' 67 (5):879-888. Sequist, Martins, et al. (2008). First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations, 'Journal of clinical oncology : official journal of the American Society of Clinical Oncology' 26 (15):2442-2449. Shepherd, Cobbe, et al. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group, 'The New England journal of medicine' 333 (20):1301-1307. Tenesa Dunlop (2009). New insights into the aetiology of colorectal cancer from genome-wide association studies, 'Nature reviews. Genetics' 10 (6):353-358. Terzic, Grivennikov, et al. (2010). Inflammation and colon cancer, 'Gastroenterology' 138 (6):2101-2114 e2105. Thomas Coley (2003). Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein, 'Cancer control : journal of the Moffitt Cancer Center' 10 (2):159-165. Toyota, Ahuja, et al. (1999). CpG island methylator phenotype in colorectal cancer, 'Proceedings of the National Academy of Sciences of the United States of America' 96 (15):8681-8686. Treanor Quirke (2007). Pathology of colorectal cancer, 'Clinical oncology' 19 (10):769-776. Tredan, Galmarini, et al. (2007). Drug resistance and the solid tumor microenvironment, 'Journal of the National Cancer Institute' 99 (19):1441-1454. Valenzuela-Fernandez, Cabrero, et al. (2008). HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions, 'Trends in cell biology' 18 (6):291-297. Van Cutsem Oliveira (2009). Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up, 'Annals of oncology : official journal of the European Society for Medical Oncology / ESMO' 20 Suppl 4 61-63. Vaupel (2004). Tumor microenvironmental physiology and its implications for radiation oncology, 'Seminars in radiation oncology' 14 (3):198-206. Vazquez, Bond, et al. (2008). The genetics of the p53 pathway, apoptosis and cancer therapy, 'Nature reviews. Drug discovery' 7 (12):979-987. Villagra, Sotomayor, et al. (2010). Histone deacetylases and the immunological network: implications in cancer and inflammation, 'Oncogene' 29 (2):157-173. Weichert, Roske, et al. (2008a). Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy, 'British journal of cancer' 98 (3):604-610. Weichert, Roske, et al. (2008b). Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo, 'Clinical cancer research : an official journal of the American Association for Cancer Research' 14 (6):1669-1677. Weis, Heeschen, et al. (2002). Statins have biphasic effects on angiogenesis, 'Circulation' 105 (6):739-745. West Johnstone (2014). New and emerging HDAC inhibitors for cancer treatment, 'The Journal of clinical investigation' 124 (1):30-39. Whittaker, Demierre, et al. (2010). Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma, 'Journal of clinical oncology : official journal of the American Society of Clinical Oncology' 28 (29):4485-4491. Wiech, Fisher, et al. (2009). Inhibition of histone deacetylases: a pharmacological approach to the treatment of non-cancer disorders, 'Current topics in medicinal chemistry' 9 (3):257-271. Wilson Hay (2011). Targeting hypoxia in cancer therapy, 'Nature reviews. Cancer' 11 (6):393-410. Winawer, Fletcher, et al. (2003). Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence, 'Gastroenterology' 124 (2):544-560. Winawer, Stewart, et al. (2000). A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group, 'The New England journal of medicine' 342 (24):1766-1772. Wong, Dimitroulakos, et al. (2002). HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis, 'Leukemia' 16 (4):508-519. Wu Grunstein (2000). 25 years after the nucleosome model: chromatin modifications, 'Trends in biochemical sciences' 25 (12):619-623. Yang, Liu, et al. (2010). Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies, 'Cancer research' 70 (19):7699-7709. Yang Seto (2008). The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men, 'Nature reviews. Molecular cell biology' 9 (3):206-218. Yao, Gietema, et al. (2005). In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo, 'British journal of cancer' 93 (12):1356-1363. Yoo, Lopez-Soler, et al. (2006). Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab, 'Clinical colorectal cancer' 6 (3):202-207. Zhang, Adachi, et al. (2006). Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis, 'Cell death and differentiation' 13 (1):129-140. 衛生福利部國民健康署 (2014). 中華民國100年癌症登記年報. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56378 | - |
| dc.description.abstract | 大腸直腸癌為全球發生率排名第三之癌症，遠端轉移為致死主因。轉移性大腸直腸癌為無法治癒之疾病，標靶藥物加上複方化學治療可延長病患存活時間至2年以上，為目前轉移性大腸直腸癌之治療準則，如何增加藥物療效、克服抗藥性、及新藥開發以延長病患存活時間為目前研究之重要方向。我們所開發的JMF compound是一具HDAC inhibitor與Statin活性之小分子藥物，本實驗發現JMF與Oxaliplatin併用可經由促進細胞凋亡克服hypoxia下之抗藥性，具加成性抑制細胞之作用。利用Xenograft模式、大腸直腸癌肝轉移模式和AOM/DSS誘發之大腸直腸癌模式測試合併JMF與Oxaliplatin於動物模式之效果，合併用藥可加成性抑制腫瘤之生長，促進凋亡，降低腫瘤內HIF-1與VEGF之表現，更可增加E-cadherin及減少轉錄因子Slug之表現抑制EMT進行。以上結果顯示JMF是一極具潛力之抗癌藥物，可與現有化療藥物併用克服hypoxia引發之抗藥性並增加化療藥物對大腸直腸癌之療效。 | zh_TW |
| dc.description.abstract | Colorectal cancer is the third most common cancer in the world, metastases are the main cause of death in colorectal cancer. Metastatic colorectal cancer is incurable, target therapy combined with chemotherapy regimens increases patient median survival and has been the standard practice for metastatic colorectal cancer. Improve the efficacy of treatment for metastatic colorectal cancer, overcome drug resistance and drug development to prolong patient survival time are the main focus of medical research. We have designed and synthesized the JMF compound which is a dual inhibitor of HDAC and HMGR. In this study, we showed that JMF combined with Oxaliplatin can overcome hypoxia-induced resistance and synergistically inhibit cell proliferation in colorectal cancer cells . We used xenograft model、CRC metastasis to liver model and AOM/DSS induced CRC model to test the effect of JMF combined with Oxaliplatin in vivo. Combined therapy has synergistic effect of tumor inhibition in vivo, it induces apoptosis, decreases HIF-1 and VEGF expression, increases E-cadherin expression and decrease Slug expression to inhibit EMT. These findings demonstrate that JMF combined with chemotherapy as a promising strategy to colorectal cancer treatment can overcome hypoxia-induced drug resistance and improve therapeutic effects. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T05:25:49Z (GMT). No. of bitstreams: 1 ntu-103-R01443019-1.pdf: 9347248 bytes, checksum: 394f8ec2c86bde0e5f4dc2bc28ecdd65 (MD5) Previous issue date: 2014 | en |
| dc.description.tableofcontents | 縮寫表………………………………………………………………………………………………………………………2
中文摘要…………………………………………………………………………………………………………………..5 英文摘要…………………………………………………………………………………………………………………..6 第一章 緒論……………………………………………………………………………………………………………..7 第一節 大腸直腸癌（Colorectal cancer）………………………………………………………8 第二節 HDACinhibitor……………………………………………………………………………………19 第三節 Statin…………………………………………………………………………………………………32 第四節 Drug resistance …………………………………………………………………………………37 第五節 研究動機……………………………………………………………………………………………51 第二章 實驗材料與方法..………………………………………………………………………………………52 第三章 結果………..…………………………………………………………………………………………………58 第四章 討論……………………………………………………………………………………………………………73 第五章 結論……………………………………………………………………………………………………………77 參考文獻…………………………………………………………………………………………………………………79 | |
| dc.language.iso | zh-TW | |
| dc.subject | 化療 | zh_TW |
| dc.subject | 大腸直腸癌 | zh_TW |
| dc.subject | Colorectal cancer | en |
| dc.subject | Chemotherapy | en |
| dc.title | Epigenetic藥物增加化療藥物在大腸直腸癌療效之研究 | zh_TW |
| dc.title | Epigenetic drugs enhance the therapeutic effect of chemotherapy in colorectal cancer | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 102-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 吳明賢(Ming-Shiang Wu),黃偉謙(Wei-Chien Huang) | |
| dc.subject.keyword | 大腸直腸癌,化療, | zh_TW |
| dc.subject.keyword | Colorectal cancer,Chemotherapy, | en |
| dc.relation.page | 89 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2014-08-14 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥理學研究所 | zh_TW |
| 顯示於系所單位： | 藥理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-103-1.pdf 未授權公開取用 | 9.13 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。